Association between frequent CpG island methylation and HER2 amplification in human breast cancers

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 466-471

  Terada, Kotoe ^a,b   Okochi Takada, Eriko ^a   Akashi Tanaka, Sadako ^c   Miyamoto, Kazuaki ^d   Taniyama, Kiyomi ^d   Tsuda, Hitoshi ^c   Asada, Kiyoshi ^a   Kaminishi, Michio ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; CPG ISLAND; DISEASE CLASSIFICATION; DNA METHYLATION; GENE AMPLIFICATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION;

BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE AMPLIFICATION; HUMANS; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 62349087940     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp021     Document Type: Article

References (32)

1. Herman,J.G. et al. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
2. Baylin,S.B. et al. (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 6, 107-116.
3. Esteller,M. (2007) Cancer epigenomics: DNA methylomes and histonemodification maps. Nat. Rev. Genet., 8, 286-298.
4. Jones,P.A. et al. (2007) The epigenomics of cancer. Cell, 128, 683-692.
5. Chen,R.Z. et al. (1998) DNA hypomethylation leads to elevated mutation rates. Nature, 395, 89-93.
6. Gaudet,F. et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science, 300, 489-492.
7. Nakagawa,T. et al. (2005) DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. J. Urol., 173, 243-246.
8. Rodriguez,J. et al. (2006) Chromosomal instability correlates with genomewide DNA demethylation in human primary colorectal cancers. Cancer Res., 66, 8462-9468.
9. Kondo,Y. et al. (2000) Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology, 32, 970-979.
10. Toyota,M. et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA, 96, 8681-8686.
11. Weisenberger,D.J. et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet., 38, 787-793.
12. Abe,M. et al. (2005) CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res., 65, 828-834.
13. Abe,M. et al. (2007) Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett., 247, 253-258.
14. King,C.R. et al. (1985) Amplification of a novel v-erb -related gene in a human mammary carcinoma. Science, 229, 974-976.
15. Slamon,D.J. et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
16. Arteaga,C.L. (2003) Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res., 5, 96-100.
17. Hudis,C.A. (2007) Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med., 357, 39-51.
18. Miyamoto,K. et al. (2005) Identification of 20 genes aberrantly methylated in human breast cancers. Int. J. Cancer, 116, 407-414.
19. Enomoto,S. et al. (2007) Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci., 98, 1853-1861.
20. Li,B. et al. (2007) The role of chromatin during transcription. Cell, 128, 707-719.
21. Ushijima,T. (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer, 5, 223-231.
22. Sakamoto,G. et al. (2005) General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer, 12 (suppl.), S1-S27.
23. Kaneda,A. et al. (2004) Decreased expression of the seven ARP2/ 3 complex genes in human gastric cancers. Cancer Lett., 212 203-210.
24. Taniyama,K. et al. (2008) Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer, 15, 231-240.
25. Van Rompay,A.R. et al. (1999) Identification of a novel human adenylate kinase. cDNA cloning, expression analysis, chromosome localization and characterization of the recombinant protein. Eur. J. Biochem., 261, 509-517.
26. Reference database for gene Expression Analysis (RefExA). http://www.Isbm.org/database/index.html.
27. Ogino,S. et al. (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut, 55, 1000-1006.
28. Fiegl,H. et al. (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res., 66, 29-33.
29. Simon,R. et al. (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst., 93, 1141-1146.
30. Li,S. et al. (2006) DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett., 237, 272-280.
31. Widschwendter,M. et al. (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res., 64, 3807-3813.
32. Feng,W. et al. (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res., 9, R57.